Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX)
Vista Partners announced that it has updated coverage on Soligenix, Inc. (“The Company” or “SNGX”) (Ticker: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, with a twelve-month price target of $4.50. Ross Silver, Principal Analyst at Vista Partners, stated, “Randal J. Kirk, the CEO of Intrexon which has approximately a $4.3B market cap, has a beneficial ownership position of approximately 20% of Soligenix. In addition, Paolo Cavazza’s beneficial ownership position on his own behalf and on behalf of Sigma-Tau is approximately 10% of Soligenix.” Mr. Silver concludes, “Soligenix recently reported positive preliminary data from the Phase 2 trial of their clinical candidate SGX942 for the treatment of oral mucositis associated with head & neck cancers. It is estimated that 500,000 patients suffer from oral mucositis, including 40% of patients receiving chemotherapy. On the conference call with investors to discuss the preliminary data of the SGX942 Phase 2 trial, Dr. Christopher Schaber (CEO of Soligenix) stated that he believed the Net Present Value of SGX942 alone was $100M or greater.” The market cap of Soligenix on April 18, 2016 was approximately $22M, 4x less than the $100M stated value of SGX942 according to management.
The iShares Nasdaq Biotechnology (NasdaqGM: IBB), a popular biotech ETF, has gained approximately 6% so far in the month of April.